Skip Navigation


Rheumatology Advance Access originally published online on June 23, 2009
Rheumatology 2009 48(9):1017-1018; doi:10.1093/rheumatology/kep164
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/9/1017    most recent
kep164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kelly, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, C.
Related Collections
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial

Leflunomide and the lung

Clive Kelly1

1Department of Rheumatology, Queen Elizabeth Hospital, Tyne and Wear, UK

Correspondence to: Clive Kelly, Department of Rheumatology, Queen Elizabeth Hospital, Sheriff Hill, Gateshead, Tyne and Wear NE96SX, UK. E-mail: clive.kelly@ghnt.nhs.uk

The first 10% of the full text of this article appears below.

SIR, LEF was licensed for the treatment of RA in the USA in 1998 and in the European Union a year later [1]. It rapidly gained a substantial share of the DMARD market in the West, with rheumatologists often prescribing LEF in preference to MTX for RA patients with established lung disease. However, following its launch in Japan in 2003, adverse pulmonary events were reported with accelerated interstitial lung disease (ILD) leading to several deaths [2, 3]. McCurry [4] detailed this development in 16 RA patients with a high associated mortality. Descriptions . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?